185 related articles for article (PubMed ID: 9608830)
1. [Preliminary treatment results of relapsed or refractory acute leukemia using two and three drug regimens].
Mariańska B; Apel D; Seferyńska I; Maj S
Wiad Lek; 1998; 51(1-2):42-5. PubMed ID: 9608830
[TBL] [Abstract][Full Text] [Related]
2. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
3. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
[TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
[TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Tallman MS; Lee S; Sikic BI; Paietta E; Wiernik PH; Bennett JM; Rowe JM
Cancer; 1999 Jan; 85(2):358-67. PubMed ID: 10023703
[TBL] [Abstract][Full Text] [Related]
6. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
Specchia G; Pastore D; Carluccio P; Liso A; Mestice A; Rizzi R; Ciuffreda L; Pietrantuono G; Liso V
Ann Hematol; 2005 Nov; 84(12):792-5. PubMed ID: 16047203
[TBL] [Abstract][Full Text] [Related]
7. Management of acute promyelocytic leukemia relapse in the ATRA era.
Castagnola C; Lunghi M; Corso A; Tajana M; Zappasodi P; Dabusti M; Lazzarino M; Bernasconi C
Haematologica; 1998 Aug; 83(8):714-7. PubMed ID: 9793255
[TBL] [Abstract][Full Text] [Related]
8. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
9. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
[TBL] [Abstract][Full Text] [Related]
11. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
Yavuz S; Paydas S; Disel U; Sahin B
Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
[TBL] [Abstract][Full Text] [Related]
12. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
13. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia.
Weiss MA; Aliff TB; Tallman MS; Frankel SR; Kalaycio ME; Maslak PG; Jurcic JG; Scheinberg DA; Roma TE
Cancer; 2002 Aug; 95(3):581-7. PubMed ID: 12209751
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
Giebel S; Krawczyk-Kulis M; Adamczyk-Cioch M; Jakubas B; Palynyczko G; Lewandowski K; Dmoszynska A; Skotnicki A; Nowak K; Holowiecki J;
Ann Hematol; 2006 Oct; 85(10):717-22. PubMed ID: 16832677
[TBL] [Abstract][Full Text] [Related]
15. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
Pastore D; Specchia G; Carluccio P; Liso A; Mestice A; Rizzi R; Greco G; Buquicchio C; Liso V
Ann Hematol; 2003 Apr; 82(4):231-5. PubMed ID: 12707726
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy.
Mehta DR; Foon KA; Redner RL; Raptis A; Agha M; Hou JZ; Duggal S; Luong TM; Schlesselman JJ; Boyiadzis M
Leuk Res; 2011 Jul; 35(7):885-8. PubMed ID: 21315448
[TBL] [Abstract][Full Text] [Related]
18. [Preliminary results of the treatment of acute leukemia with mitoxantrone].
Rozmysłowicz T; Pałynyczko G; Mazur J; Konecki R; Apel D; Mariańska B; Maj S; Hołowiecki J; Rudzka E; Lawniczek T
Acta Haematol Pol; 1991; 22(1):69-81. PubMed ID: 1823970
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study.
Choi SJ; Lee JH; Lee JH; Kim S; Lee YS; Seol M; Ryu SG; Lee JS; Kim WK; Jang S; Park CJ; Chi HS; Lee KH
Bone Marrow Transplant; 2005 Jul; 36(2):163-9. PubMed ID: 15937507
[TBL] [Abstract][Full Text] [Related]
20. Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule.
Damon LE; Johnston LJ; Ries CA; Rugo HS; Case D; Ault K; Linker CA
Cancer Chemother Pharmacol; 2004 Jun; 53(6):468-74. PubMed ID: 15138711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]